Literature DB >> 699245

Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure.

C Curtiss, J N Cohn, T Vrobel, J A Franciosa.   

Abstract

In 15 patients with severe chronic left ventricular failure, plasma renin activity (PRA) ranged widely, from 0.2--39 ng/ml/hr. The level of PRA was unrelated to cardiac output (CO) or pulmonary artery wedge pressure (PWP), but was slightly negatively correlated with mean arterial pressure (MAP) (r = -0.45) and systemic vascular resistance (SVR) (r = -0.40). After infusion of the angiotensin converting enzyme inhibitor teprotide (SQ 20,881) PWP fell from 26.3 +/- 1.3 (SEM) to 20.3 +/- 1.4 mm Hg (P less than 0.001), CO rose from 3.94 +/- 0.23 to 4.75 +/- 0.31 l/min (P less than 0.001), MAP fell from 87.5 +/- 3.8 to 77.9 +/- 4.1 mm Hg (P less than 0.001) and SVR from 1619 +/- 148 to 1252 +/- 137 dyne-sec-cm-5 (P less than 0.001). The fall in MAP and in SVR was significantly correlated with control PRA (r = 0.68 and r = 0.58, respectively). When subjects were divided on the basis of control PRA the hemodynamic response to teprotide was greatest in the high renin group. PRA rose after teprotide (8.7 +/- 3.4 to 37.9 +/- 7.7 ng/ml/hr, P less than 0.05) but plasma norepinephrine fell (619.1 +/- 103.6 to 449.7 +/- 75.7, P less than 0.05). The renin-angiotensin system thus appears to have an important role in the elevated SVR in some patients with heart failure. Chronic inhibition of converting enzyme should be explored as a possible therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 699245     DOI: 10.1161/01.cir.58.5.763

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  54 in total

Review 1.  Nitric oxide, cell death, and heart failure.

Authors:  Jun-ichi Oyama; Stefan Frantz; Charles Blais; Ralph A Kelly; Todd Bourcier
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

2.  Afterload reduction in the therapy of heart failure.

Authors:  W H Fennell
Journal:  Tex Heart Inst J       Date:  1982-03

3.  Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

4.  Cell death, tissue hypoxia and the progression of heart failure.

Authors:  H N Sabbah; V G Sharov; S Goldstein
Journal:  Heart Fail Rev       Date:  2000-06       Impact factor: 4.214

5.  Hemodynamic phenotype of the failing Fontan in an adult population.

Authors:  Camden L Hebson; Nancy M McCabe; Robert W Elder; William T Mahle; Michael McConnell; Brian E Kogon; Emir Veledar; Maan Jokhadar; Robert N Vincent; Anurag Sahu; Wendy M Book
Journal:  Am J Cardiol       Date:  2013-09-25       Impact factor: 2.778

6.  Effects of captopril on pulmonary haemodynamics.

Authors:  C Richard; J L Ricome; A Rimailho; M Conrad; P Auzépy
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure.

Authors:  S K Mujais; F M Fouad; S C Textor; R C Tarazi; E L Bravo; N Hart; R W Gifford
Journal:  Br Heart J       Date:  1984-07

8.  Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatraemia.

Authors:  P Nicod; J Biollaz; B Waeber; J J Goy; R Polikar; J Schlapfer; M D Schaller; G A Turini; J Nussberger; K G Hofbauer
Journal:  Br Heart J       Date:  1986-11

9.  Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.

Authors:  P W Armstrong
Journal:  Can Med Assoc J       Date:  1979-10-06       Impact factor: 8.262

10.  The effect of angiotensin II and noradrenaline alone and in combination on renal sodium excretion in man.

Authors:  P H Seidelin; J J McMurray; R A Brown; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.